Savient Pharmaceuticals Inc. (Nasdaq: SVNT) announced a delay of its FDA review for a gout drug candidate and the dismissal of its CFO sending shares of the biopharmaceutical plunging $1.36 to close at $5.94.
Savient Delays Review For Gout Drug
February 13, 2009 at 17:02 PM EST
